Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
BoxX-NoAF Clinical Trial
NCT06989775 · View on ClinicalTrials.gov ↗
Study Summary
Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial to evaluate if prophylactic ablation and exclusion of the Left Atrial Appendage at the time of other routine cardiac surgery can reduce the incidence of post operative AF and clinical AF during long term follow up in patients who have not yet developed AF but are at risk.
Conditions Studied
Interventions
- DEVICE Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
Study Locations (10)
Florida
- Morton Plant Hospital - BayCare Health System, Inc. — Clearwater
- St. Joseph's Hospital - BayCare Health System, Inc. — Clearwater
- Orlando Health, Inc. — Orlando
Arkansas
- St. Bernards Medical Center — Jonesboro
Georgia
- Wellstar Health System — Marietta
Michigan
- Corewell Health — Grand Rapids
Minnesota
- Mayo Clinic — Rochester
New York
- New York Presbyterian Hospital/Columbia University Irving Medical Center — New York
Tennessee
- Ascension Saint Thomas — Nashville
Ontario
- Hamilton General Hospital — Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2031-11 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06989775
The ClinicalTrials.gov registry entry for NCT06989775 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Post Operative Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention — of which Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06989775 reports 10 study locations spanning 8 distinct geographic areas — top geographies include Florida, Arkansas, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06989775 about?
NCT06989775 is a clinical study titled "BoxX-NoAF Clinical Trial". Post Operative Atrial Fibrillation (POAF) is the most common complication of cardiac surgery. POAF incidence can exceed 50% depending on the patient baseline characteristics and surgery type. Patients with POAF tend to have worse acute and long-term clinical outcomes. BoxX-NoAF is a randomized trial...
What is the current status of trial NCT06989775?
This trial is currently recruiting. It is a NA study. The enrollment target is 960 participants. The study started on 2025-10-24. Estimated completion is 2031-11.
What conditions does trial NCT06989775 study?
This clinical trial studies the following conditions: Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06989775?
The interventions under investigation include: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06989775?
This trial is sponsored by AtriCure, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06989775 being conducted?
This trial has 10 study locations across Arkansas, Florida, Georgia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.